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ABSTRACT 
Complement assays have for many years utilised buffers based on barbitone 
(veronal) despite the well-recognised toxicity of this agent and the tight regulations 
on its use in most countries. The use of barbitone in complement assay buffers is 
steeped in history, from a time when no other suitable buffers were available. This 
is no longer the case, encouraging us to explore alternatives to barbitone for 
complement assays. We compared a simple, non-toxic HEPES buffer with 
commercially sourced complement fixation test diluent (CFD), the “gold standard” 
barbitone buffer, in several clinically relevant complement activity assays and 
across species.  
In classical pathway haemolysis assays in human and non-human serum, there 
was no difference in haemolytic curves or calculated haemolytic activity (CH50) 
between CFD and an optimised HEPES buffer (HBS) supplemented with cations. 
Alternative pathway haemolysis assays in human serum were also identical in the 
two buffers.  In a complement fixation test for anti-erythrocyte antibodies, 
complement consumption was identical for the two buffer systems.  
The data demonstrate that barbitone-based buffers are unnecessary for assays of 
complement activity and can readily be replaced with safe and simple 
alternatives. 
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INTRODUCTION  
With the increasing recognition of roles of complement activation in disease and 
the growing list of drugs that target complement, it is becoming ever more 
important to have simple and safe assays for complement activity that can be 
replicated across the globe (Morgan et al., 2015; Sim et al., 2016).  Traditionally, 
assays of complement activity have involved measuring the haemolytic activity of a 
test sample for either antibody-sensitised sheep erythrocytes (ShEA) or 
unsensitised rabbit or guinea pig erythrocytes (RbE; GpE) to test the classical and 
alternative pathways respectively (Pillemer et al., 1943; Lachmann et al., 2006; 
Mayer et al., 1946; Morgan et al., 2000; Ghebrehiwet et al., 1997; Barnum et al., 
2018). Complement fixation tests that have been widely used to measure antigen-
antibody reactions also rely on quantification of residual haemolytic activity to 
assess the degree of fixation – actually, consumption – in the first incubation 
(Whillas et al., 1950; Breadstreet et al., 1962). These assays have, for more than 
70 years, been performed in barbitone (5,5-diethyl barbituric acid) buffers, also 
called barbital or “veronal”, at pH ~7.3 with physiological salt concentration and 
supplemented with Ca2+ and Mg2+ ions. These buffers were selected because they 
offered good buffering capacity at a pH optimal for complement activity and were 
non-chelating for Ca2+ and Mg2+ ions.  
Barbitone is a long-acting barbiturate, the first to be made commercially available 
as a hypnotic drug and widely used for this purpose from the 1900s to the mid-
1950s (Norn et al., 2015; Lopez – Munoz et al. 2005). “Veronal” was the trade 
name under which the agent was marketed by Bayer. Accidental (and deliberate) 
overdoses were common, often resulting in death, in part a consequence of its 
small therapeutic margin (Lopez – Munoz et al., 2005; Bateman et al., 1963). As a 
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consequence, barbitone and its sodium salt, also used in buffer preparation, are 
listed by the US Drug Enforcement Administration (DEA) as a schedule IV 
controlled substance and subject to strict control on transport, storage and record-
keeping (http://www.controlleddrugs.org/Schedules.html).  In many other countries, 
barbitone is subject to stringent restrictions on supply and in an increasing number 
it is banned completely. The risks and restrictions have resulted in the replacement 
of buffers based on barbitone for other applications, for example in 
immunoelectrophoresis, by safer and more readily accessible buffers (Monthony et 
al., 1978; Anani et al., 2015). In contrast, the use of barbitone-based buffers for 
complement assays has continued.  Although there have been isolated 
publications that have utilised alternative buffers for complement assays (Moreno–
Indias et al., 2012), there has been no formal testing and comparison of these with 
CFD or other barbitone buffers.  Here we describe such a comparison. We show 
that a buffer based on HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid), a zwitterionic buffer with excellent buffering capacity at pH7.4 and no 
significant toxicity, can be used in place of CFD and related barbitone buffers in 
classical and alternative pathway complement haemolytic assays and in 
complement fixation tests without any impact on test outcome.      
 
Materials and methods 
All chemicals, except where otherwise stated, were obtained from either Fisher 
Scientific UK (Loughborough, Leicestershire, UK) or Sigma Aldrich (Gillingham, 
Dorset, UK) and were of analytical grade. 
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Human and animal sera were prepared in-house from freshly collected blood. For 
human, rabbit, rat and guinea pig, blood was clotted at room temperature for 1 
hour, and then placed on ice for 2 hours for clot retraction prior to centrifugation 
and harvesting of serum.  For mouse, blood was placed on ice immediately after 
harvest and clotted for 2 hours on ice prior to serum harvest. Sera were stored in 
aliquots at -800C. In some studies serum was heat-inactivated by incubation at 
600C for 30 minutes. 
 
Buffer preparation 
HBS buffer was prepared with concentrations of 0.01 M HEPES, 0.15 M NaCl, 
135 nM CaCl2, 1 mM MgCl2, at final pH 7.4. 
CFD was prepared by dissolving one CFD buffer tablet (Oxoid, #BR0016) in 
100ml deionised water; the resultant buffer contained 3 mM barbitone 
(C8H12N2O3), 900 nM sodium barbitone (C8H11N2NaO3), 0.15 M NaCl, 250 nM 
CaCl2,  2 mM MgCl2, at final pH 7.2 (Oxoid BT-SPEC 0026). 
Alternative pathway buffer (APB) was prepared by adding EGTA 
(Ethyleneglycoltetraacetic Acid, from 0.5M EGTA stock) to a final concentration of 
5 mM and additional MgCl2 to 3mM final concentration into test buffer (HBS or 
CFD). 
 
Haemolytic Assays 
HEPES buffer was tested against CFD in haemolytic assays using antibody-
sensitised sheep erythrocytes (ShE; sheep blood from TCS Bioscience, 
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Buckingham, UK) for classical pathway and guinea pig erythrocytes (GpE: blood 
from TCS) for alternative pathway. ShE were antibody-sensitised (ShEA) by 
incubation for 15 minutes at 37°C with a 1:2000 dilution in phosphate-buffered 
saline of rabbit anti-sheep erythrocyte antiserum (#ORLC25, Siemens Amboceptor; 
Cruinn Diagnostics Ltd., Dublin, UK) and washed into the test buffer at 2% final 
(vol:vol). For measurement of classical pathway complement activity in male 
mouse serum, ShEA were additionally incubated with mouse anti-rabbit IgG 
(#3123, at 20µg/ml, Invitrogen; Paisley, UK) for 30 minutes at 37°C prior to washing 
into test buffer. GpE were directly washed into the test buffer at 2% final.  Cells in 
test buffer were aliquoted into wells of a 96-well round-bottomed plate (50 µl/well) 
followed by 50 µl/well of serum dilutions (in triplicate) in the same test buffer. A 
further 50µl/well of the test buffer was added to each well and plates sealed and 
incubated at 37oC for 30 minutes. Plates were then centrifuged and haemoglobin in 
the supernatant measured by absorbance at 415nm. Percentage lysis was 
calculated according to: % Lysis =100*(Absorbance (Abs) sample-Abs 
background)/(Abs max -Abs background). The 50% haemolytic complement 
activity (CH50 for classical, AH50 for alternative pathway) was calculated for each 
lytic curve (Morgan et al., 2000). In some assays, normal serum was mixed with 
heat-inactivated serum to create a low complement activity serum.  
To test the impact of the buffers on screening for complement deficiencies, sera 
depleted of C5 or deficient in C6 or C8 were diluted 1 in 10 in the appropriate buffer 
and aliquoted in to wells of a 96 well plate as above. Purified terminal pathway 
proteins (C5, C6, C7, C8, C9; physiological levels for each) were added in triplicate 
to separate sets of wells for each of the depleted/deficient sera. ShEA were added 
to each well, incubated and absorbance read as above.   
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Complement Fixation Test (CFT) 
Human erythrocytes from a blood group A-positive donor (HuEA+) were washed, 
suspended to 2% in test buffer (HBS or CFD) and 500 µl aliquots placed in four 
tubes. Serum from a blood group 0-positive donor (1:10 dilution in test buffer, 500 
µl/tube) was added and pairs of tubes incubated either at 370C or on ice for 30 
minutes.  As an additional control, A-positive erythrocytes were incubated with A-
positive serum as above. Tubes were centrifuged at 40C, supernatant removed, 
and a serial dilution series prepared, 50 µl/well in triplicate in the test buffer. ShEA 
at 1% in test buffer were added (100 µl/well), plates were sealed and incubated at 
37oC for 30 minutes, centrifuged and haemoglobin in the supernatant measured by 
absorbance at 415nm. Percentage lysis was calculated according to: % Lysis 
=100*(Absorbance (Abs) sample - Abs background)/(Abs max - Abs 
background)%. CH50 was calculated for each lytic curve (Morgan et. al, 2000). 
 
Stability Testing 
To test the effect of the test buffers on erythrocyte stability we utilised the protocol 
described by Oxoid (BT-SPEC-0026). Fresh sheep blood (1ml) was added to 10ml 
of test buffer (CFD or HBS) and incubated at 37°C for 20 hours; 0.5ml samples 
were removed at time points; 0.3, 3, 6 and 20 hours, aliquoted 150 µl/well in 
triplicate wells of a 96-well round-bottomed plate, centrifuged and haemoglobin in 
the supernatants measured by absorbance at 415nm. Controls included blood 
incubated with deionised water or 0.1% Tween 20 in deionised water. Percentage 
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lysis was calculated according to: % Lysis =100*(Absorbance (Abs) sample-Abs 
background)/(Abs max -Abs background) %.  
 
RESULTS 
HBS is indistinguishable from barbitone-based buffer in haemolytic assays 
For assessment of classical pathway activity, HBS containing Ca2+ and Mg2+ was 
compared with commercially sourced CFD containing Ca2+ and Mg2+. ShEA in the 
relevant buffer were incubated with a dilution series of human or non-human 
(rabbit, guinea pig, rat and mouse) sera. With each of the sera tested, the lytic 
curves obtained in the two buffers were superimposed, and the calculated CH50 
values for each serum in the two buffers were the same (Figure 1 A-E).  For 
assessment of alternative pathway activity, HBS was supplemented with Mg2+ and 
EGTA to generate an alternative pathway-specific buffer (no Ca2+); this was 
compared to CFD similarly supplemented with Mg2+ and EGTA (alternative 
pathway buffer; APB). Only human serum was tested in this assay.  The lytic 
curves obtained in the two buffers were superimposed and the calculated AH50 
values for the serum in the two buffers were the same (Figure 1 F).  
To test the capacity of the buffers to measure low levels of haemolytic activity, NHS 
was diluted with heat-inactivated NHS (1:3) and tested as above; lytic curves and 
calculated CH50 values were identical in the two buffers (Figure 2A).  
To test the utility of the HBS buffer for identifying complement component 
deficiencies, add-back studies to deficient or depleted sera were performed. For 
each serum tested, HBS and CFD showed identical results and correctly identified 
the missing component (Figure 2 B-D).    
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HBS is indistinguishable from barbitone-based buffer in a complement 
fixation test 
To compare the buffers in a complement fixation test, A-positive HuE were 
incubated in the relevant buffer with group O serum containing anti-A antibodies, 
either on ice to inhibit fixation or at 37°C to facilitate fixation (Petz et al., 1974). After 
this incubation, the serum was tested in a classical pathway assay in the same 
buffer to measure residual complement activity. Incubation on ice in either buffer 
did not reduce lytic activity of the serum, whereas incubation at 37°C resulted in a 
~90% reduction in classical pathway activity in each buffer (CH50; samples 
incubated at 37°C in HBS average HU= 20.7, in CFD = 22.4; samples incubated on 
ice in HBS average HU= 111.2, in CFD = 100.5) (Figure 3 A, B). Incubation of A-
positive HuE with A-positive serum caused no reduction in complement activity at 
either temperature and in either buffer, confirming that consumption was 
dependent on antigen-antibody complexes. (Figure 3 C, D). 
 
Erythrocytes are stable on storage in HBS 
To compare the stability of ShE in CFD and HBS, sheep blood was diluted in HBS 
or CFD and incubated at 37°C for up to 20 hours. In either buffer ShE displayed no 
lysis across the time course. In control incubations with deionised water or 0.1% 
tween 20, all cells were lysed within 30 minutes. The data demonstrate that HBS is 
compatible with and can be used for storage of target erythrocytes.  
 
Discussion 
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Over the last twenty years, interest in complement, particularly its roles in disease 
and suitability as a therapeutic target has exploded (Morgan et al., 2015, Ricklin et 
al., 2013). There is thus an increased need for robust, reliable and generalisable 
assays of complement activation and activity (Harboe et al., 2011; Bergseth et al., 
2013). Studies on characterisation of complement activity and its interactions 
require reliable tools. A major stumbling block has been the dependence on 
barbitone-containing buffers both for measuring complement activity and 
complement fixation.  Commercial barbitone-based complement fixation test diluent 
(CFD) tablets and concentrates have been widely marketed for decades and 
became the gold standard for complement haemolytic assays; however, they are 
increasingly difficult to access, impossible in many countries. Their continued use 
for complement assays is a historical artefact, dating back more than 70 years to a 
time when the choice of available buffers was much smaller and barbitone-based 
buffers offered excellent buffering in the optimal pH range for complement activity 
and no interference with complement activation (Levine et al., 1953; Heidelberger 
et al., 1941; Eagle et al., 1929). 
The use of barbitone-based buffers for complement assays is an anachronism. 
Given the disadvantages inherent in the use of a buffer that is toxic and heavily 
regulated, it is surprising that this practice has survived into the 21st century. We 
here demonstrate that barbitone has no place in complement assays; it can readily 
be replaced by easily available, safe and relatively inexpensive alternatives that do 
not impact assay performance.  
We chose to test a HEPES-based buffer system based upon: 1. published BiaCore 
evidence that complement convertases formed efficiently in the recommended 
BiaCore HBS-P buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% v/v Surfactant 
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P20) supplemented with excess Ca2+ and Mg2+ (Harris et al., 2007; Paixao – 
Cavalcante et al., 2012); 2. the fact that HEPES is a strong buffer in the optimal pH 
range for complement assays; 3. that it does not chelate divalent cations essential 
for complement activity and 4. that it is non-toxic. Other equally suitable buffer 
systems undoubtedly exist.   
Our optimal HEPES-buffered saline (HBS; 0.01 M HEPES pH 7.4, 0.15 M NaCl, 
supplemented with Ca2+ and Mg2+) was directly compared with commercial 
barbitone buffer (CFD) in haemolysis assays in human and non-human serum and 
serum modified to have low haemolytic activity, in a complementation study to 
define terminal pathway component deficiencies and in a complement fixation test. 
In all cases, haemolysis was obtained in HBS and the lytic curves for HBS and 
CFD were superimposed.  Calculated CH50 and AH50 values for the sera tested 
were essentially identical in HBS and CFD assays (AH50; HBS, 22.4 HU, CFD, 
20.7 HU). CH50 values were also identical when serum modified to have ~30% of 
normal haemolytic activity was tested. In the complementation study, HBS and 
CFD showed the same results in identifying terminal pathway deficiencies. In the 
complement fixation test, consumption in the first incubation was the same in HBS 
and CFD as shown by identical measures of residual lytic activity in the second 
incubation (haemolysis).    
We comprehensively demonstrate that barbitone buffers are not necessary for 
assays requiring efficient complement activation; a simple HEPES-based buffer 
yields identical results. We hope that these findings will help laboratories establish 
robust assays of complement activity and activation that will have broad 
applicability for diagnosis of disease and monitoring of therapy.  
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FIGURE LEGENDS 
Figure 1. HBS tested in haemolytic assay (CH50, AH50) in comparison to CFD 
buffer. ShEA in the relevant buffer were incubated with a dilution series of human 
or animal (rabbit, guinea pig, rat and mouse) sera. With each of the sera tested, the 
lytic curves obtained in the two buffers were superimposed, and the calculated 
CH50 values for each serum in the two buffers were the same (A-E).  For 
assessment of alternative pathway activity, HBS supplemented with Mg2+ and 
EGTA was compared to CFD supplemented with Mg2+ and EGTA (alternative 
pathway buffer; APB). Only human serum was tested in this assay (AH50).  The 
lytic curves obtained in the two buffers were superimposed and the calculated 
AH50 values for the serum in the two buffers were the same (F). CFD; complement 
fixation diluent, APB; alternative pathway buffer, HBS; HEPES buffer. The assays 
were performed a minimum of three times with the same outcome.  
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Figure 2. Compering HBS and CFD under conditions of low complement activity 
and for confirmation of component deficiency. A) Normal human serum (NHS) or 
NHS mixed 1:3 with heat inactivated NHS was tested in haemolysis assays diluted 
in CFD or HBS. Haemolysis was identical in the two buffers under both conditions. 
B) Sera depleted of C5 (C5D) or deficient in C6 (C6D) or C8 (C8D) were diluted 
1:10 in either HBS or CFD. The terminal pathway proteins C5, C6, C7, C8 and C9 
were added in physiological amounts to triplicate sets of wells and incubated. The 
percentage lysis was calculated for each condition and shown as means of 
triplicates (+/-SE).  100% lysis (NHS and 0.1% Tween20) and 0% (deficient serum 
alone and no serum) controls were included.  
Figure 3. Complement fixation test (CFT) results. To compare the buffers in a 
complement fixation test, A-positive human erythrocytes (HuE) were incubated in 
the relevant buffer with group O serum containing anti-A antibodies, either on ice to 
inhibit fixation or at 37°C. After this incubation, the serum was tested in a classical 
pathway assay (CH50) in the same buffer to measure residual complement activity, 
replicate assays are shown (A, B). Incubation on ice in either buffer did not reduce 
lytic activity of the serum, whereas incubation at 37°C resulted in a ~90% reduction 
in classical pathway activity in each buffer (CH50; samples incubated at 37°C in 
HBS average HU= 20.7, in CFD = 22.4; samples incubated on ice in HBS average 
HU= 111.2, in CFD = 100.5). Controls were subject to the same incubations but 
with group A serum replacing group O (C, D); no consumption was seen. 
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Figure 2 
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Figure 3 
 
         A)																																																																																																	B) 
 
CFD test
0.1 1 10 100
0
20
40
60
80
100
120
Rep 1 37°C       21.9
Rep 2 37°C       22.8
Rep 1 4°C        100.9
Rep 2 4°C        100.0
CH50(HU)
Serum dose (µl)
Ly
si
s 
(%
)
	
       C)                                                                          D)     
CFD control
0.1 1 10 100
0
20
40
60
80
100
120
Rep 1 37°C      109.2
Rep 2 37°C      111.8
Rep 1 4°C        117.0
Rep 2 4°C        116.1
CH50(HU)
Serum dose (µl)
Ly
si
s 
(%
)
	 
	
 
 
	
 
 
 
HBS test
0.1 1 10 100
0
20
40
60
80
100
120
Rep 1 37°C       20.3
Rep 2 37°C       21.1
Rep 1 4°C        108.0
Rep 2 4°C        114.4
CH50(HU)
Serum dose (µl)
Ly
si
s 
(%
)
HBS control
0.1 1 10 100
0
20
40
60
80
100
120
Rep 1 37°C      70.6
Rep 2 37°C      64.3
Rep 1 4°C        67.5
Rep 2 4°C        62.4
CH50(HU)
Serum dose (µl)
Ly
si
s 
(%
)
